News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–32
Matches
32
Sources here
8
Companies here
1
Search results Stored financial headlines

Active search

32 matching headlines

Ticker or company: ENLVMain company stories
Clear
Latest

Stock Titan Market update

Enlivex Ltd. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing by Enlivex Ltd. (NASDAQ: ENLV) on August 14, 2026, which was a Notice of Effectiveness for an F-3 form. The filing was accepted by the SEC EDGAR system on the same day. The article also provides an overview of Enlivex Ltd.'s recent news and SEC filings.

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Stock Titan Deals and strategy Main company 🇺🇸 United States

Enlivex Ltd. (ENLV) sees 9.99% stake reported via convertible note

Lind Global Asset Management XIV, LLC, The Lind Partners, LLC, and Jeff Easton have reported beneficial ownership of 9.99% of Enlivex Ltd.'s ordinary shares through a Senior Secured Convertible Promissory Note. The note includes a clause preventing conversion that would lead to ownership exceeding …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Enlivex (ENLV) revises $21M secured convertible note, adds 10% interest trigger

Enlivex Ltd. has amended its $21.0 million secured convertible promissory note with Lind Global Asset Management XIV, LLC. The amendment removes a market capitalization-related event of default and waives a previous default, while increasing the outstanding principal from $16.3 million to $19.2 million. A …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Enlivex Therapeutics Ltd (ENLV), highlighting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts project a target price of $7.00 for ENLV, with one analyst recommending a "Buy" rating. The report …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Enlivex Ltd. (NASDAQ: ENLV) files to register 10M shares for noteholder resale

Enlivex Ltd. (NASDAQ: ENLV) has filed a Form F-3 to register up to 10,000,000 ordinary shares for resale by Lind Global Asset Management XIV, LLC. These shares are related to a previously issued Senior Secured Convertible Promissory Note worth $21.0 million, for which Enlivex …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

H.C. Wainwright raises Enlivex stock price target to $80 on token gains

H.C. Wainwright has significantly raised its price target for Enlivex Therapeutics (NASDAQ:ENLV) to $80 from $20, maintaining a Buy rating, citing the substantial increase in value of the RAIN token. Despite the bullish outlook driven by the RAIN token's 3,000% gain over the past …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Enlivex Is Maintained at Buy by HC Wainwright & Co.

HC Wainwright & Co. has reiterated its Buy rating on Enlivex Therapeutics Ltd. The article does not provide further details on the reasons behind the rating or any specific price targets.

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Analyst action Main company 🇺🇸 United States

Enlivex Highlights 622% Surge in Rain Protocol Trading Volume to $860 Million

Enlivex Ltd. (ENLV) reported a 622% month-over-month surge in trading volume on the Rain protocol, reaching $860 million by July 29, 2026. This increase supports Rain's goal to become a leading decentralized prediction market, which is part of Enlivex's strategy to diversify operations through …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Enlivex (Nasdaq: ENLV) Rain protocol volume hits $860M, up 622%

Enlivex (Nasdaq: ENLV) announced that trading volume on its Rain protocol reached $860 million as of July 29, 2026, marking a 622% month-over-month increase. The company's digital asset treasury strategy, powered by this protocol, anticipates significant growth, with target trading volumes projected to reach …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Enlivex Therapeutics Ltd (ENLV), stating its current valuation score as 9.94, ranking 5th in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 0.08, noting its position relative to recent highs and …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Market update Main company 🇺🇸 United States

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

Enlivex Ltd. announced its management team will host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time. The webinar will provide investors with details on the company's recent private placement, the status and strategy of its RAIN treasury, and clinical …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Enlivex (Nasdaq ENLV) to host webinar on capital strategy and RMAT Allocetra

Enlivex Ltd. (Nasdaq: ENLV) will host a live investor webinar on July 30, 2026, at 10:00 AM Eastern Time to discuss its recent private placement, the strategy of its RAIN protocol-based treasury, and clinical progress for its Allocetra™ immunotherapy program. The webinar will also …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Market update Main company 🇺🇸 United States

Enlivex Announces $400,000,000 Private Placement

Enlivex Therapeutics Ltd. announced a private placement of $400 million, led by institutional investors. The financing is expected to support the company's clinical development programs and general corporate purposes. This significant investment highlights investor confidence in Enlivex's therapeutic approach.

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Deals and strategy Main company 🇺🇸 United States

Enlivex Shares Plunge After $400 Million Private Placement Deal

Enlivex Therapeutics Ltd.'s shares experienced a significant drop after the company announced a private placement deal aiming to raise $400 million. This deal involves the issuance of ordinary shares and warrants, which often leads to dilution preocupaciones among existing shareholders. The market reacted negatively, …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Enlivex (NASDAQ: ENLV) sets $400M Rain deal and $400M equity put

Enlivex Ltd. has entered into a private placement agreement with the Rain Foundation for up to $400 million in ordinary shares or pre-funded warrants, with an additional discretionary put option for Enlivex to require Rain to purchase up to another $400 million in equity …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
StocksToTrade Market update Main company 🇺🇸 United States

ENLV Stock Slides Into 1-For-15 Reverse Split On Nasdaq

Enlivex Ltd. (ENLV) executed a 1-for-15 reverse stock split to comply with Nasdaq listing rules after its stock fell below $1, causing a significant price drop of 23.47%. While the split mathematically adjusted the share price, the underlying business and clinical risks remain, making …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Enlivex (Nasdaq: ENLV) sets $400M RAIN token-linked private placement

Enlivex Ltd. has announced a $400 million private placement with a single institutional investor, involving the issuance of ordinary shares at premiums of 17.4% to 40.8% over the July 27, 2026 closing price, depending on the funding method. The investor currently plans to fund …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Enlivex investor may fund proposed $400M deal with RAIN tokens

Enlivex (Nasdaq: ENLV) has entered into a securities purchase agreement for a private placement of approximately $400 million in ordinary shares or equivalents with a single institutional investor. The investor has currently elected to fund the purchase using RAIN tokens, which offers a higher …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Enlivex Therapeutics Ltd (ENLV), detailing its support and resistance levels, various technical indicators, and moving averages. It highlights the stock's current price momentum, ranking within the Biotechnology & Medical Research industry, and offers a neutral signal based …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Deals and strategy Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides a historical overview of dividends and stock splits for Enlivex Therapeutics Ltd (ENLV). It indicates that ENLV has distributed no dividends over the past five years and lists one stock split event: a 15-to-1 merger on July 7, 2026. …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Balance Sheet

This article presents the annual and quarterly balance sheets for Enlivex Therapeutics Ltd (ENLV), allowing users to evaluate the company's financial health, fundamentals, and key ratios. It includes detailed financial data from FY2015Q1 to FY2025Q4 across assets, liabilities, and shareholders' equity. The document also …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Income Statement

This article provides the quarterly and annual income statements for Enlivex Therapeutics Ltd (ENLV), offering financial data from Q1 2014 to Q4 2025. It details various financial metrics including revenue, operating expenses, R&D expenses, operating profit, and net income. The page also includes FAQs …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Cash Flow

This article provides a detailed historical cash flow statement for Enlivex Therapeutics Ltd (ENLV), breaking down operating, investing, and financing activities from FY2015Q1 to FY2025Q4. It includes key financial metrics like net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Enlivex Therapeutics Ltd (ENLV). It indicates that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company. The page also presents basic financial information like market …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Institutional Confidence

The article provides a snapshot of Enlivex Therapeutics Ltd (ENLV) focusing on its institutional confidence score as part of TradingKey's stock analysis. As of July 24, 2026, the company has a market capitalization of $66.47 million and a P/E TTM of 0.16. The institutional …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Enlivex Therapeutics Ltd (ENLV), listing its major shareholders and institutional holdings. It shows that Gems Foundation, Token Factory, Sobrinia Ltd, Heaven Consulting Corp, and Alfa Ltd are the largest shareholders, holding significant percentages. The report also provides …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

ENLV|Enlivex Therapeutics Ltd|Price:4.200|Chg%:-0.160

Enlivex Therapeutics Ltd (ENLV) is currently trading at $4.200, down 3.67%. Despite weak fundamentals, the company has high growth potential and is considered fairly valued in the Biotechnology & Medical Research industry. Analysts provide a "Buy" rating with a target price of $300.00, indicating …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 98.2%

Short interest in Enlivex Therapeutics (NASDAQ:ENLV) significantly decreased by 98.2% to 26,452 shares as of July 15, down from 1.51 million shares at the end of June. The short-interest ratio is now 0.4 days, representing about 0.2% of shares sold short. Despite mixed analyst …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Earnings Main company 🇺🇸 United States

Enlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share

Enlivex announced an update on its RAIN token-based treasury, reporting a net asset value per ordinary share of $66.16 as of July 18, 2026. The company holds approximately 79.55 billion RAIN tokens valued at $1.1 billion. While maintaining a significant digital asset portfolio, Enlivex's …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Earnings Main company 🇺🇸 United States

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

Enlivex Ltd. announced an update on its RAIN token holdings as of July 18, 2026. The company reported a net asset value (NAV) per ordinary share of $66.16 and held 79,550,593,122 RAIN tokens, collectively valued at approximately $1.1 billion. Enlivex is a longevity company …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Enlivex’s Net Asset Value Per Share Was $66.16 on July 18

Enlivex (NASDAQ: ENLV) reported its net asset value (NAV) per ordinary share was $66.16 as of July 18, 2026. The company held over 79.5 billion RAIN tokens, valued at approximately $1.1 billion, based on CoinMarketCap closing prices. These unaudited mark-to-market valuations are part of …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Enlivex (Nasdaq: ENLV) details $1.1B RAIN token holdings and NAV

Enlivex Ltd. (Nasdaq: ENLV) announced an update on its digital asset treasury, reporting a net asset value per ordinary share of $66.16 as of July 18, 2026. The company holds approximately 79.55 billion RAIN tokens, valued at about $1.1 billion. This strategy combines its …

ENLV main company
Sharemaestro market context Price below Trend Line 52 weeks -90.0% · Next-week setup negative 37.1% ENLV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context